A safety assessment of MRT‐2359 in combination with AR inhibitor enzalutamide for previously treated metastatic prostate cancer, as well as combination with ER inhibitor fulvestrant for previously treated metastatic estrogen receptor‐positive breast cancer, was initiated in 2022 (NCT05546268). This evidence concerns the gene ESR1 and metastatic prostate carcinoma.